Рак простаты

What’s New On Radiotherapy of Prostate Cancer in 2026?

What’s New On Radiotherapy of Prostate Cancer in 2026? Oncodaily

Researchers identify critical window for boosting immunotherapy response in prostate cancer

Researchers at Roswell Park Comprehensive Cancer Center have shown that hormone-blocking therapies commonly used to treat prostate cancers temporarily activate the body's immune response before those immune effects begin to fade over time. In a new publication in the Journal for Immunotherapy of Cancer, a team led by…

Advancements in Classifying Prostate Cancer Can Inform Treatment Decisions

Advancements in Classifying Prostate Cancer Can Inform Treatment Decisions Labroots

New ASTRO Guideline Backs Hypofractionated Radiation in Prostate Cancer

ASTRO updates prostate cancer treatment guideline

ASTRO updates prostate cancer treatment guideline AuntMinnie

FDA Approved Talazoparib Plus Enzalutamide for HRR-Mutated Metastatic Castration-Sensitive Prostate Cancer

FDA Approved Talazoparib Plus Enzalutamide for HRR-Mutated Metastatic Castration-Sensitive Prostate Cancer Oncodaily

Stamford Health offers ultrasound option to treat back pain and prostate cancer

Stamford Health offers ultrasound option to treat back pain and prostate cancer CT Insider

Stamford Health offers ultrasound option to treat back pain and prostate cancer

Stamford Health offers ultrasound option to treat back pain and prostate cancer Stamford Advocate

Shorter Radiation Courses Become Standard Care for Localized Prostate Cancer in New Guideline

Shorter Radiation Courses Become Standard Care for Localized Prostate Cancer in New Guideline Bioengineer.org

Novel alpha radiopharmaceutical therapy shows promise in early-phase prostate cancer trial

A new alpha-emitting radiopharmaceutical therapy (RPT) for advanced prostate cancer was well tolerated, with no dose-limiting toxicities observed, and showed encouraging signs of antitumor activity, according to a trial published in The Journal of Nuclear Medicine's Late-Breaking Fast Track.

Guideline on shorter-course radiation therapy for localized prostate cancer updated

An updated clinical guideline from the American Society for Radiation Oncology (ASTRO) provides evidence-based recommendations on the use of hypofractionated radiation therapy for patients with localized prostate cancer. The guideline replaces ASTRO's 2018 recommendations and reflects a matured evidence base showing…

Updated ASTRO guidelines recommend shorter radiation courses for prostate cancer - News-Medical

Updated ASTRO guidelines recommend shorter radiation courses for prostate cancer News-Medical

FDA OKs Talzenna, enzalutamide combo for prostate cancer

The FDA has expanded its approval of talazoparib in combination with enzalutamide to include men with metastatic androgen pathway modulation-naive or -sensitive prostate cancer with homologous recombination repair gene mutations. “This approval represents a critical advancement for patients with newly diagnosed…

ACT Brief: Community Trial Cost Barriers, Measuring What Matters, and Prostate Cancer Approval

ACT Brief: Community Trial Cost Barriers, Measuring What Matters, and Prostate Cancer Approval Applied Clinical Trials Online

FDA Approves a New Treatment Option for Metastatic Prostate Cancer

FDA Approves a New Treatment Option for Metastatic Prostate Cancer Labroots